Atricure, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Matson from Needham reiterated a Buy rating on the stock and has a $45.00 price target.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Michael Matson has given his Buy rating due to a combination of factors including Atricure’s strong financial performance in the third quarter of 2025. The company exceeded expectations in revenue, EBITDA, and EPS, and subsequently raised its guidance for 2025. Despite a slight slowdown in revenue growth, Atricure’s gross and operating margins improved significantly, with the latter turning positive for the first time.
Furthermore, Atricure generated substantial cash flow during the quarter, which strengthens its financial position. Matson views the company’s guidance and future estimates as conservative, suggesting that upcoming product launches could further enhance revenue and EBITDA. These positive financial indicators and growth potential underpin Matson’s Buy rating for Atricure’s stock.
Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ATRC in relation to earlier this year.